Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal Esophageal- Gastric Junction Cancer

  • STATUS
    Recruiting
  • End date
    Dec 31, 2027
  • participants needed
    200
  • sponsor
    The Second Hospital of Shandong University
Updated on 28 January 2021

Summary

Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.

Details
Condition Esophageal Diseases, Esophageal Disorders, Esophageal Cancer, Esophageal Cancer, Immunostimulant, Pharmaceutical Adjuvants, head and neck cancer, head and neck cancer, Immunotherapy, Esophageal Carcinoma, Gastroesophageal Cancer, Esophageal Disorders, immunomodulator, immunostimulants, immunomodulators, immunological adjuvant, immunologic adjuvant, esophagus cancer, oesophageal cancer, immunotherapies, cancer of the esophagus, oesophageal carcinoma
Treatment Immunotherapy, Chemotherapy Drugs, Cancer
Clinical Study IdentifierNCT04688801
SponsorThe Second Hospital of Shandong University
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven esophageal or EG-junction carcinoma (Siewert I-II). The
heart and lung function can tolerate surgery. The cancer is resectable and
incurable therapy will be perfomed

Exclusion Criteria

EG-junction carcinoma (Siewert III). M1 stage according to the current (8th)
version of TNMclassification system. The heart and lung function can't
tolerate surgery. R2 Resection Status
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note